Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044549328> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W3044549328 endingPage "291S" @default.
- W3044549328 startingPage "286S" @default.
- W3044549328 abstract "Present the case of a 67-year-old male with stage IV malignant melanoma who presented with uveitis and sensorineural hearing loss (SNHL) while on nivolumab and review the literature for likely etiologies.A retrospective case review was conducted. The current literature was accessed to inquire about possible pathologic mechanisms and treatment options.A 67-year-old male with stage IV malignant melanoma was treated with nivolumab. During therapy, the patient presented with bilateral uveitis, vertigo, and bilateral moderate sloping to moderate-severe SNHL. After 4 cycles of nivolumab, restaging scans showed no evidence of disease. Nivolumab was discontinued. The patient was placed on a 3-week course of systemic high dose steroids and topical steroid eye drops. Both his uveitis and SNHL resolved after treatment. Nivolumab enhances the antitumor activity of T cells by inhibiting the programed death-1 receptor. While nivolumab has shown great promise in the treatment of many types of cancers, it has also been associated with many autoimmune side effects. We propose the etiology of this 67-year-old male's SNHL and uveitis are the result of an autoimmune process secondary to an augmented T cell response induced by nivolumab.While immunotherapeutic agents such as nivolumab have shown great promise in the treatment of cancer, one should maintain an awareness and caution of autoimmune side effects such as uveitis and SNHL." @default.
- W3044549328 created "2020-07-29" @default.
- W3044549328 creator A5027650544 @default.
- W3044549328 creator A5061858983 @default.
- W3044549328 creator A5063392256 @default.
- W3044549328 creator A5066204067 @default.
- W3044549328 date "2020-07-23" @default.
- W3044549328 modified "2023-10-18" @default.
- W3044549328 title "Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma" @default.
- W3044549328 cites W1902123239 @default.
- W3044549328 cites W2050302632 @default.
- W3044549328 cites W2070326078 @default.
- W3044549328 cites W2104750134 @default.
- W3044549328 cites W2132916434 @default.
- W3044549328 cites W2153942285 @default.
- W3044549328 cites W2153965826 @default.
- W3044549328 cites W2155464214 @default.
- W3044549328 cites W2284755230 @default.
- W3044549328 cites W2310090962 @default.
- W3044549328 cites W2509332865 @default.
- W3044549328 cites W2547133566 @default.
- W3044549328 cites W2588008593 @default.
- W3044549328 cites W2619461121 @default.
- W3044549328 cites W2619530510 @default.
- W3044549328 cites W2810537535 @default.
- W3044549328 cites W2896600825 @default.
- W3044549328 cites W2918786853 @default.
- W3044549328 cites W2948217212 @default.
- W3044549328 doi "https://doi.org/10.1177/0145561320940847" @default.
- W3044549328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32703012" @default.
- W3044549328 hasPublicationYear "2020" @default.
- W3044549328 type Work @default.
- W3044549328 sameAs 3044549328 @default.
- W3044549328 citedByCount "8" @default.
- W3044549328 countsByYear W30445493282020 @default.
- W3044549328 countsByYear W30445493282021 @default.
- W3044549328 countsByYear W30445493282022 @default.
- W3044549328 countsByYear W30445493282023 @default.
- W3044549328 crossrefType "journal-article" @default.
- W3044549328 hasAuthorship W3044549328A5027650544 @default.
- W3044549328 hasAuthorship W3044549328A5061858983 @default.
- W3044549328 hasAuthorship W3044549328A5063392256 @default.
- W3044549328 hasAuthorship W3044549328A5066204067 @default.
- W3044549328 hasBestOaLocation W30445493281 @default.
- W3044549328 hasConcept C118487528 @default.
- W3044549328 hasConcept C121608353 @default.
- W3044549328 hasConcept C126322002 @default.
- W3044549328 hasConcept C137627325 @default.
- W3044549328 hasConcept C143998085 @default.
- W3044549328 hasConcept C16005928 @default.
- W3044549328 hasConcept C2776194053 @default.
- W3044549328 hasConcept C2777658100 @default.
- W3044549328 hasConcept C2777701055 @default.
- W3044549328 hasConcept C2780030458 @default.
- W3044549328 hasConcept C502942594 @default.
- W3044549328 hasConcept C71924100 @default.
- W3044549328 hasConceptScore W3044549328C118487528 @default.
- W3044549328 hasConceptScore W3044549328C121608353 @default.
- W3044549328 hasConceptScore W3044549328C126322002 @default.
- W3044549328 hasConceptScore W3044549328C137627325 @default.
- W3044549328 hasConceptScore W3044549328C143998085 @default.
- W3044549328 hasConceptScore W3044549328C16005928 @default.
- W3044549328 hasConceptScore W3044549328C2776194053 @default.
- W3044549328 hasConceptScore W3044549328C2777658100 @default.
- W3044549328 hasConceptScore W3044549328C2777701055 @default.
- W3044549328 hasConceptScore W3044549328C2780030458 @default.
- W3044549328 hasConceptScore W3044549328C502942594 @default.
- W3044549328 hasConceptScore W3044549328C71924100 @default.
- W3044549328 hasIssue "3_suppl" @default.
- W3044549328 hasLocation W30445493281 @default.
- W3044549328 hasLocation W30445493282 @default.
- W3044549328 hasOpenAccess W3044549328 @default.
- W3044549328 hasPrimaryLocation W30445493281 @default.
- W3044549328 hasRelatedWork W1582278270 @default.
- W3044549328 hasRelatedWork W2122205087 @default.
- W3044549328 hasRelatedWork W2262554279 @default.
- W3044549328 hasRelatedWork W2418168712 @default.
- W3044549328 hasRelatedWork W2900818500 @default.
- W3044549328 hasRelatedWork W2955428297 @default.
- W3044549328 hasRelatedWork W2969687411 @default.
- W3044549328 hasRelatedWork W2981372661 @default.
- W3044549328 hasRelatedWork W3002986063 @default.
- W3044549328 hasRelatedWork W4361939482 @default.
- W3044549328 hasVolume "100" @default.
- W3044549328 isParatext "false" @default.
- W3044549328 isRetracted "false" @default.
- W3044549328 magId "3044549328" @default.
- W3044549328 workType "article" @default.